Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Potential Partner Backpedals From Emisphere Insulin Deal

March 6, 2003

By Aaron Lorenzo

Financially Uncertain Essential Seeks To Divest Some Assets

March 6, 2003

By Aaron Lorenzo

Financially Uncertain Essential Seeks To Divest Some Assets

March 6, 2003

By Aaron Lorenzo

Potential Partner Backpedals From Emisphere Insulin Deal

March 6, 2003

By Aaron Lorenzo

Viragen Continues Restructuring To Sustain Remaining Resources

March 5, 2003

By Aaron Lorenzo

YM BioSciences Receives FDA Nod For Phase III Cancer Trial

March 5, 2003

By Aaron Lorenzo

YM BioSciences Receives FDA Nod For Phase III Cancer Trial

March 5, 2003

By Aaron Lorenzo

Viragen Continues Restructuring To Sustain Remaining Resources

March 5, 2003

By Aaron Lorenzo

AnorMED's Fosrenol Receives Approvable Letter From FDA

March 4, 2003

By Aaron Lorenzo

The regulatory approval horizon appears closer than ever for the kidney disease drug Fosrenol. (BioWorld Today)

AnorMED's Fosrenol Receives Approvable Letter From FDA

March 4, 2003

By Aaron Lorenzo

The regulatory approval horizon appears closer than ever for the kidney disease drug Fosrenol. (BioWorld Today)

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 9, 2025.
100 days of uncertainty
BioWorld
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
AACR 2025: Induced proximity strategy, beyond degraders
BioWorld
Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
NME Digest: Q1 2025
BioWorld
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...